X4 Pharmaceuticals (XFOR) Depreciation & Amortization (CF) (2017 - 2025)

X4 Pharmaceuticals has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $223000.0 in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 18.32% year-over-year to $223000.0; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (up 60.43% YoY), and the FY2025 full-year result was $1.3 million, up 60.43% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $223000.0, roughly flat from $223000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $476000.0 in Q1 2025, with the low at $62000.0 in Q4 2023.
• Historically, Depreciation & Amortization (CF) has averaged $175200.0 across 5 years, with a median of $132000.0 in 2021.
• Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) plunged 51.18% — and 2025, when it surged 667.74%.
• X4 Pharmaceuticals' Depreciation & Amortization (CF) stood at $132000.0 in 2021, then declined by 6.06% to $124000.0 in 2022, then slumped by 50.0% to $62000.0 in 2023, then soared by 340.32% to $273000.0 in 2024, then dropped by 18.32% to $223000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $223000.0 (Q4 2025), $223000.0 (Q3 2025), and $355000.0 (Q2 2025), per Business Quant data.